In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 3, 1997, Pages 583-586

  Thadepalli, Haragopal ^a,b,c   Reddy, Umapathi ^a   Chuah, See Kean ^a   Thadepalli, Fernando ^a,c   Malilay, Cicero ^a   Polzer, Robert J ^d   Hanna, Nancy ^a   Esfandiari, Adeleh ^a   Brown, Perry ^a   Gollapudi, Sastry ^a,c  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b School of Medicine   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; CLINDAMYCIN; GENTAMICIN; TROVAFLOXACIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL ABSCESS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDES FRAGILIS; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; IMMUNOREGULATION; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031019078     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.3.583     Document Type: Article

References (20)

1. Bach, V. T., and H. Thadepalli. 1980. Susceptibility of anaerobic bacteria in vitro to antimicrobial agents. Chemotherapy (Basel) 26:344-353.
2. Bailey, S., M. Faye, and M. Gougerot-Pocidalo. 1990. Effect of quinolones on TNF production by human monocytes. Int. J. Immunopharmacol. 12:31-36.
3. Beutler, B., and A. Cerami. 1986. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature (London) 320:584-588.
4. Beutler, B., W. Milsark, and A. Cerami. 1985. Passive immunization against cachectin/TNF protects mice from lethal effects of endotoxin. Science 229: 869-871.
5. Edelstein, P. H., and M. A. C. Edelstein, J. Ren, R. Polzer, and R. P. Gladue. 1996. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vivo activity, intracellular accumulation, and killing in macrophages and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 40:314-319.
6. Fleiss, J. L. 1980. Statistical methods for rates and proportions, 2nd ed. Wiley, New York, N.Y.
7. Girard, A. E., D. Girard, T. D. Gootz, J. A. Faiella, and C. R. Cimochowski. 1995. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens Streptococcus pneumoniae and Bacteroides fragilis. Antimicrob. Agents Chemother. 39:2210-2216.
8. Gollapudi, S., S. K. Chuah, T. Harvey, H. D. Thadepalli, and H. Thadepalli. 1993. In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis. Antimicrob. Agents Chemother. 37:1711-1712.
9. Jacobs, R. F., and D. R. Tabor. 1990. The immunology of sepsis and meningitis - cytokine biology. Scand. J. Infect. Dis. 73:(Suppl.)7-15.
10. Lundbald, R., P. Ekstrom, and K. E. Giercksky. 1995. Pemoxifylline improves survival and reduces tumor necrosis factor, interleukin-6 and endothilin-1 in fulminant intra-abdominal sepsis in rats. Shock 3:210-215.
11. Nemunaitis, J., C. Rosenfeld, L. Getty, F. Boegel, W. Meyer, L. W. Jennigs, Z. Zeigler, and R. Shadduck. 1995. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am. J. Clin. Oncol. 18:189-193.
12. Neu, H. N., and N. Chin. 1994. In vitro activity of the new, fluoroquinolone CP-99,219. Antimicrob. Agents Chemother. 38:2615-2622.
13. Teng, R., D. R. Brennan, T. G. Tensfeldt, T. E. Liston, and G. Foulds. 1993. Determination of CP-99,219, a new oral quinolone antibiotic, in biological samples by reverse phase high performance liquid chromatography. Pharm. Res. 10:S56.
14. Thadepalli, H., S. L. Gorbach, P. Broido, and J. Norsen. 1972. A prospective study of infections in penetrating abdominal trauma. Am. J. Clin. Nutt. 25:1405-1408.
15. Thadepalli, H., M. Bansal, M. B. Rao, R. See, S. K. Chuah, R. Marshal, et al. 1988. Ciprofloxacin: in vitro, experimental and clinical evaluation. Rev. Infect. Dis. 10:505-515.
16. Thadepalli, H., S. V. Gollapudi, and S. K. Chuah. 1986. Therapeutic evaluation of difloxacin (A-56619) and A56620 for experimentally induced Bacteroides fragilis associated intra-abdominal abscess. Antimicrob. Agents Chemother. 30:574-576.
17. Thadepalli, H., M. Hajji, V. K. Perumal, S. K. Chuah, and S. Gollapudi. 1992. Evaluation of temafloxacin in a rat model of intra-abdominal abscess. J. Antimicroh. Chemother. 29:687-692.
18. Tracey, K. J., S. F. Lowry, T. J. Fahey, J. D. Albert, D. Hesse, B. Beutler, K. R. Manogue, S. Sealvano, H. Wei, and A. Cerami. 1987. Cachectin and tumor necrosis factor induces lethal shock and stress hormone response in the dog. Surg. Gynecol. Obstet. 164:415-420.
19. Weistein, W. M., A. B. Onderdonk, J. G. Bartlett, and S. L. Gorbach. 1984. Experimental intra-abdominal abscess in rats. Development of an animal model. Infect. Immun. 10:1250-1259.
20. Yasumoto, R., M. Kawano, T. Tsujino, Y. Iwai, N. Nishisaka, A. Hori, and T. Kishimoto. 1995. Seminal plasma cytokines in nonbacterial prostatis: changes following sparofloxacin treatment. Acta Urol. Jpn. 41:771-774.